

CHIMERIX INC  
Form 8-K  
September 29, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**September 26, 2014**

Date of Report (Date of earliest event reported)

**Chimerix, Inc.**

Edgar Filing: CHIMERIX INC - Form 8-K

(Exact name of registrant as specified in its charter)

**Delaware**                      **001-35867**                      **33-0903395**  
(State or other jurisdiction (Commission File Number) (IRS Employer Identification No.)  
of incorporation)

**2505 Meridian Parkway, Suite 340**  
**Durham, NC**                                              **27713**  
(Address of principal executive offices)                      (Zip Code)

**Registrant's telephone number, including area code: (919) 806-1074**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- ..      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- ..      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- ..      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- ..      Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4©)

**Item 7.01 Regulation FD Disclosure.**

On October 11, 2014, Chimerix, Inc. (the “*Company*”) is scheduled to present at ID Week 2014 in Philadelphia, PA, in a presentation titled “Preliminary safety results and antiviral activity from the open-label pilot portion of a Phase 3 study to evaluate Brincidofovir (BCV) for the treatment of adenovirus (ADV) infection”.

An abstract summarizing the Company’s scheduled presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Forward-Looking Statements**

Statements contained in, or incorporated by reference into, this Current Report on Form 8-K regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company’s filings with the Securities and Exchange Commission, including without limitation the Company’s most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	Chimerix, Inc. presentation abstract.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Chimerix, Inc.**

Dated: September 26, 2014

By: /s/ Timothy W. Trost  
Timothy W. Trost  
Senior Vice President,  
Chief Financial Officer  
and Corporate  
Secretary

**INDEX TO EXHIBITS**

Exhibit No.	Description
99.1	Chimerix, Inc. presentation abstract.